MAP
RNAC icon

Madison Avenue Partners’s Cartesian Therapeutics RNAC Stock Holding History

Madison Avenue Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,420
Closed -$402K – 21
2023
Q4 		$402K Sell
19,420
-114,181
-85% -$3.41M 0.06% 18
2023
Q3 		$4.25M Buy
+133,601
New +$4.46M 0.6% 14

Other funds holding RNAC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Madison Avenue Partners's RNAC Position: Q1 2024 in Review

Madison Avenue Partners sold out of Cartesian Therapeutics (RNAC) in Q1 2024, closing a stake of 19,420 shares — an estimated $402K sold.

Madison Avenue Partners first reported a position in RNAC in Q3 2023 and held it in 2 quarters. The position peaked at $4.25M in Q3 2023. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

  • Madison Avenue Partners reported no remaining Cartesian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Madison Avenue Partners sold 19,420 Cartesian Therapeutics shares in Q1 2024, an estimated $402K.
  • Madison Avenue Partners first reported a position in Cartesian Therapeutics in Q3 2023 and held it in 2 quarters.
  • Madison Avenue Partners's Cartesian Therapeutics position peaked at $4.25M in Q3 2023.
  • 69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on Madison Avenue Partners's 13F filing for Q1 2024, filed 15 May 2024.